EMG Announces Appointment of Shaun Gregory as New Group Chief Executive Officer
11.5.2021 09:30:00 EEST | Business Wire | Press release
EMG, a leading global provider of broadcast facilities and media solutions, announced today that Shaun Gregory will join the company as Group Chief Executive Officer starting May 17th 2021. Gregory is a seasoned executive with over 30 years of experience in the media, telecommunications & broadcasting industries. He has served as Chief Executive Officer for some of the fastest growing companies, both in Europe and globally.
Under his leadership, EMG will continue the development of its ambitious transformation strategy. He will succeed co-CEO Patrick van den Berg who after 15 years serving in various leadership positions at EMG will take on a new professional challenge while co-CEO François-Charles Bideaux will become advisor to the CEO & EMG board focusing on specific areas such as sales, technology and M&A.
Most recently, Gregory was CEO of media localization company IYUNO Media Group (formerly BTI Studios) which spans 46 countries and 88 language types, servicing the world’s leading entertainment brands, including Netflix and Disney. In this role, he was responsible for developing a market leading strategy, transforming the business and the creation of a new global market leader in media localisation. Prior to IYUNO, Gregory was Chief Executive Officer at Exterion Media, Europe’s largest privately held out of home advertising company. At Exterion Media, Shaun was appointed Chief Executive in 2014, and was successfully awarded the world’s biggest outdoor advertising contract, The London Underground. Exterion operated across markets in Europe, including the UK, Ireland, Netherlands, France and Spain. Both companies enjoyed market beating growth under private equity ownership, with Exterion sold to Global in 2018.
Prior to IYUNO and Exterion, Gregory was the Global Managing Director of Telefonica’s media and content businesses. He was responsible for 34 markets, including most of Latin America, having emerged out of his UK role at O2. He was credited with a number of launches, including O2 Priority in the UK, and created new and innovative ways of delivering content to consumers. Before his time at Telefonica he spent almost 15 years at EMAP, Europe’s fastest growing media company where he was a key architect in the company’s digital transformation, winning several licences (analogue and digital), spanning radio and television. In addition, EMAP was pivotal in the launch of the UK’s digital terrestrial television platform Freeview.
Patrick van den Berg commented: “First of all a warm welcome to Shaun. After my 15 years in different leadership positions within EMG and finally as co-CEO, it is important for me that a seasoned executive with a broad and international experience takes over as CEO. Given Shaun’s background I am confident that he will lead EMG into future successes. I would like to take this opportunity to thank everybody at EMG as well as our founders and investors, for everything we realized and for the group we built together. It has been a great adventure and although it is time for me to take on a new professional challenge, I will surely keep on following the amazing company which is EMG.”
“On behalf of the board of EMG, I would like to thank Patrick for his contribution in making EMG the success it is today and wish him all the best in his next challenge,” added Fabrice Fouletier, Partner at PAI Partners, the majority shareholder in EMG. “We are thrilled to have appointed someone with Shaun’s credentials. He has an excellent track record, that spans over 30 years, in both listed and private equity backed companies. He has operated at the most senior level of some of the fastest growing companies in our sector and has done that successfully through innovation and a relentless focus on growth. His international and transformation experience will provide a strong platform for EMG, and I am confident that he will lead the company into a new and exciting chapter.”
Shaun Gregory said: “I’m excited to be joining the EMG Team, and can’t wait to continue the great work that’s been going on there. I see these as pivotal moments in the broadcasting and live events industry. As the world returns to normality, the appetite for what EMG delivers to people around the globe will become ever more important. EMG have played an acute role in getting people through the challenges of the pandemic, delivering some of the world’s most prestigious sporting events. As we look forward to happier times, I’m thrilled to be part of a new growth story and delivering the raw emotions and experiences to audiences around the world.”
He added: “The industry will need to innovate with new technological solutions, and EMG are already leading the way. Our customers and partners will have changing needs, as the landscape develops, and I’m looking forward to us being ahead of the curve. It’s not just about innovation, it’s also about taking a very ‘customer-centric’ approach to everything we do, and that’s one thing that EMG is all about – great customer service, innovation and ultimately a world class delivery. I’m very proud to be joining the Team, and providing the Leadership for the next chapter.”
Gregory has also served as a non-Executive Director of both listed and private equity backed companies. He also serves on the Childline Board (NSPCC) and the Advisory Board for The Sheffield Children’s Hospital. He is originally from Yorkshire in the UK, has two daughters and currently lives in London.
About EMG
EMG is a leading global provider of broadcast services and media solutions for live sports, entertainment and events, active in 10 countries: France, Belgium, the Netherlands, Germany, United Kingdom, Switzerland, Italy, Luxembourg, the USA & Australia. Constantly proposing state-of-the-art technologies through highly experienced teams, EMG is a valued partner for major international events, including sport (Tour de France, Football World Cup and Formula One…) live events (Eurovision, Royal Weddings, Concerts…) and entertainment (The Voice, Masterchef, the X-Factor…).
About PAI Partners
PAI Partners is a leading European private equity firm with offices in Paris, London, Luxembourg, Madrid, Milan, Munich, New York and Stockholm. It manages €14.7 billion of dedicated buyout funds and, since 1994, has completed 84 transactions in 11 countries, representing over €60 billion in transaction value. PAI Partners is characterised by its industrial approach to ownership combined with its sector-based organisation. It provides the companies it owns with the financial, operational and strategic support required to pursue their development and enhance value creation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005202/en/
Contact information
Press
Pauline Bénéat
pauline.beneat@emglive.com
+32 (0) 472 188 495
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
